SCHEMBL4140294

SCHEMBL4140294

COc1ccc(Nc2cc(N3CCOCC3)nc(-c3cccc(O)c3)n2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 13/20 0.70
PIK3CB P42338 4/20 0.55
PIK3CG P48736 3/20 0.55
PIK3CD O00329 2/20 0.54
MAPK1 P28482 1/20 0.53
TAAR1 Q96RJ0 1/20 0.53
GAA P10253 1/20 0.51
ROCK2 O75116 1/20 0.50
ROCK1 Q13464 1/20 0.50
GALR2 O43603 1/20 0.49
GALR1 P47211 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PIK3R1 P27986 1/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4138231 0.91 PIK3CA (0.58) PIK3CAPIK3CBPIK3CGPIK3CDROCK2
SCHEMBL4133829 0.89 PIK3CA (0.58) PIK3CAPIK3CBPIK3CGPIK3CDCYP1A2
SCHEMBL4138246 0.88 PIK3CA (0.67) PIK3CAPIK3CBPIK3CGPIK3CDMAPK1
SCHEMBL4138240 0.87 PIK3CA (0.58) PIK3CAPIK3CBPIK3CGPIK3CD
SCHEMBL4147474 0.85 ABCG2 (0.60) PIK3CAPIK3CBPIK3CGPIK3CD
SCHEMBL4131802 0.84 PIK3CA (0.56) PIK3CAPIK3CBPIK3CGPIK3CDMAPK1
SCHEMBL4143852 0.84 PIK3CA (0.57) PIK3CAPIK3CBPIK3CGPIK3CDMAPT
SCHEMBL4145858 0.82 PIK3CA (0.55) PIK3CAPIK3CBPIK3CGPIK3CDKMT2A
SCHEMBL1822046 0.82 PIK3CA (1.00) PIK3CAPIK3CBPIK3CGPIK3CDMAPK1
SCHEMBL4128479 0.82 PIK3CA (0.57) PIK3CAPIK3CBPIK3CGPIK3CDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156601-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-06-18 US claimed
EP-1945627-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2008-07-23 EP claimed
WO-2007042806-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2007-04-19 WO claimed
US-20090156601-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-06-18 US disclosed
US-20090156601-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-06-18 US disclosed
US-20090156601-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-06-18 US disclosed
EP-1945627-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2008-07-23 EP disclosed
WO-2007042806-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156601-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER NR3C1, NR4A3, NR4A1 PIK3CA 137/4885PIK3CB 377/4885PIK3CG 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.